Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HMBeacon phase 2 study of ALN-6400 in women with von Willebrand disease and heavy menstrual bleeding
NL-OMON61346Phase 2Not yet recruiting
- Sponsor
- Alnylam Pharmaceuticals
- Start
- Sep 2026
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
Phase 2, double-blind trial of ALN-6400 in von Willebrand disease (VWD) (2 arms), sponsored by Alnylam Pharmaceuticals. Primary endpoint: Frequency of adverse events. Planned start Sep 2026; status: not yet recruiting.
02
Drugs
ALN-6400
03
Conditions
von Willebrand disease (VWD)
Beyond the preview
Go deeper on NL-OMON61346.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON61346.